Transmembrane Protein 106A is Silenced by Promoter Region Hypermethylation and Suppresses Gastric Cancer Growth by Inducing Apoptosis.

Dong Xu,Liujing Qu,Jia Hu,Ge Li,Ping Lv,Dalong Ma,Mingzhou Guo,Yingyu Chen
DOI: https://doi.org/10.1111/jcmm.12352
2014-01-01
Journal of Cellular and Molecular Medicine
Abstract:Inactivation of tumour suppressor genes by promoter methylation plays an important role in the initiation and progression of gastric cancer ( GC ). Transmembrane 106A gene ( TMEM 106A ) encodes a novel protein of previously unknown function. This study analysed the biological functions, epigenetic changes and the clinical significance of TMEM 106A in GC . Data from experiments indicate that TMEM 106A is a type II membrane protein, which is localized to mitochondria and the plasma membrane. TMEM 106A was down‐regulated or silenced by promoter region hypermethylation in GC cell lines, but expressed in normal gastric tissues. Overexpression of TMEM 106A suppressed cell growth and induced apoptosis in GC cell lines, and retarded the growth of xenografts in nude mice. These effects were associated with the activation of caspase‐2, caspase‐9, and caspase‐3, cleavage of BID and inactivation of poly ( ADP ‐ribose) polymerase ( PARP ). In primary GC samples, loss or reduction of TMEM 106A expression was associated with promoter region hypermethylation. TMEM 106A was methylated in 88.6% (93/105) of primary GC and 18.1% (2/11) in cancer adjacent normal tissue samples. Further analysis suggested that TMEM 106A methylation in primary GC s was significantly correlated with smoking and tumour metastasis. In conclusion, TMEM 106A is frequently methylated in human GC . The expression of TMEM 106A is regulated by promoter hypermethylation. TMEM 106A is a novel functional tumour suppressor in gastric carcinogenesis.
What problem does this paper attempt to address?